Cargando…
Hormone exposure and venous thromboembolism in commercially insured women aged 50 to 64 years
BACKGROUND: Menopausal hormone therapy (MHT) can elevate venous thromboembolism (VTE) risk, but less is known about formulations and routes of exposures. OBJECTIVE: To estimate hormone-associated VTE risk by route and formulation in exposed and unexposed women aged 50 to 64 years in the US. METHODS:...
Autores principales: | Weller, Susan C., Davis, John W., Porterfield, Laura, Chen, Lu, Wilkinson, Gregg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182313/ https://www.ncbi.nlm.nih.gov/pubmed/37193125 http://dx.doi.org/10.1016/j.rpth.2023.100135 |
Ejemplares similares
-
Incidence of venous thrombotic events and events of special interest in a retrospective cohort of commercially insured US patients
por: Weller, Susan C, et al.
Publicado: (2022) -
First venous thromboembolism and hormonal contraceptives in young French women
por: Hugon-Rodin, Justine, et al.
Publicado: (2017) -
Endogenous sex hormones and risk of venous thromboembolism in young women
por: Scheres, Luuk J. J., et al.
Publicado: (2019) -
Menopausal hormone therapy and venous thromboembolism
por: Bińkowska, Małgorzata
Publicado: (2014) -
Venous thromboembolism in women
por: Peclat, Ana Paula Rolim Maia, et al.
Publicado: (2023)